Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial
Background Despite improved outcomes with immune checkpoint inhibitors (ICIs) and their combinations in advanced solid tumors, a subset of patients remains unresponsive or progresses, highlighting an unmet need for novel treatments with durable benefit. Nemvaleukin alfa (nemvaleukin, ALKS 4230) demo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/8/e010777.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849771505917886464 |
|---|---|
| author | Xiaomin He Emiliano Calvo David F McDermott Valentina Boni Olivier Dumas Arvind Chaudhry Sang Joon Shin Seth D Rosen Philip R Debruyne Ulka N Vaishampayan |
| author_facet | Xiaomin He Emiliano Calvo David F McDermott Valentina Boni Olivier Dumas Arvind Chaudhry Sang Joon Shin Seth D Rosen Philip R Debruyne Ulka N Vaishampayan |
| author_sort | Xiaomin He |
| collection | DOAJ |
| description | Background Despite improved outcomes with immune checkpoint inhibitors (ICIs) and their combinations in advanced solid tumors, a subset of patients remains unresponsive or progresses, highlighting an unmet need for novel treatments with durable benefit. Nemvaleukin alfa (nemvaleukin, ALKS 4230) demonstrated manageable safety and antitumor activity, alone and in combination with pembrolizumab, across heavily pretreated advanced solid tumors in the ARTISTRY-1 study. We report in-depth antitumor activity, safety, pharmacokinetics, and pharmacodynamics of nemvaleukin monotherapy at the recommended phase 2 dose (RP2D) in advanced melanoma and renal cell carcinoma (RCC) cohorts from ARTISTRY-1.Methods ARTISTRY-1 was a three-part (A, B, and C), multicenter, open-label, phase 1/2 study. Adult patients who had received prior treatment, including ICIs, and had advanced melanoma or RCC were enrolled in Part B. Patients received intravenous nemvaleukin once daily on days 1–5 (21-day cycle) at 6 µg/kg/day (RP2D determined from Part A). Primary endpoints for Part B were overall response rate (ORR) and safety. Secondary endpoints included pharmacokinetic and pharmacodynamic measures.Results From July 2016 to March 2023, 74 patients in Part B received nemvaleukin monotherapy (melanoma, n=47; RCC, n=27). ORR in melanoma and RCC cohorts was 9% (95% CI, 2% to 21%; n=4) and 14% (95% CI, 3% to 35%; n=3), respectively; disease control rate was 50% (95% CI, 35% to 65%; n=23) and 50% (95% CI, 28% to 72%, n=11), respectively, with stable disease ≥6 months observed in 3 (7%) and 2 (9%) patients, respectively. The most common nemvaleukin-related treatment-emergent adverse event of grade 3–4 was neutropenia (melanoma, n=27 (57%); RCC, n=9 (33%)). No patients in either cohort experienced grade ≥3 treatment-emergent adverse events (TEAEs) of cytokine release syndrome or infusion-related reaction. There were no reported capillary leak syndrome TEAEs. Pharmacokinetic parameters for extent and duration of nemvaleukin exposure were similar between the two cohorts. Increases in peripheral CD8+ T-cell and natural killer cell populations from baseline were similar between the two cohorts, with minimal changes in regulatory T cells observed.Conclusions Nemvaleukin demonstrated pharmacodynamic proof of mechanism, with single-agent antitumor activity and manageable safety in patients with advanced melanoma and RCC.Trial registration number NCT02799095. |
| format | Article |
| id | doaj-art-80fbfafcfc1342b0bd4e199ca8965ba1 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-80fbfafcfc1342b0bd4e199ca8965ba12025-08-20T03:02:36ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-08-0113810.1136/jitc-2024-010777Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialXiaomin He0Emiliano Calvo1David F McDermott2Valentina Boni3Olivier Dumas4Arvind Chaudhry5Sang Joon Shin6Seth D Rosen7Philip R Debruyne8Ulka N Vaishampayan99 Mural Oncology, Inc, Waltham, Massachusetts, USA1 START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain11 Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA1 START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain2 CHU de Québec-Université Laval, Québec City, Québec, Canada5 Summit Cancer Centers - Spokane Valley, Spokane, Washington, USA3 Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)4 Hematology Oncology Association of the Treasure Coast, Port St. Lucie, Florida, USA6 Kortrijk Cancer Centre, General Hospital AZ Groeninge, Kortrijk, Belgium10 Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USABackground Despite improved outcomes with immune checkpoint inhibitors (ICIs) and their combinations in advanced solid tumors, a subset of patients remains unresponsive or progresses, highlighting an unmet need for novel treatments with durable benefit. Nemvaleukin alfa (nemvaleukin, ALKS 4230) demonstrated manageable safety and antitumor activity, alone and in combination with pembrolizumab, across heavily pretreated advanced solid tumors in the ARTISTRY-1 study. We report in-depth antitumor activity, safety, pharmacokinetics, and pharmacodynamics of nemvaleukin monotherapy at the recommended phase 2 dose (RP2D) in advanced melanoma and renal cell carcinoma (RCC) cohorts from ARTISTRY-1.Methods ARTISTRY-1 was a three-part (A, B, and C), multicenter, open-label, phase 1/2 study. Adult patients who had received prior treatment, including ICIs, and had advanced melanoma or RCC were enrolled in Part B. Patients received intravenous nemvaleukin once daily on days 1–5 (21-day cycle) at 6 µg/kg/day (RP2D determined from Part A). Primary endpoints for Part B were overall response rate (ORR) and safety. Secondary endpoints included pharmacokinetic and pharmacodynamic measures.Results From July 2016 to March 2023, 74 patients in Part B received nemvaleukin monotherapy (melanoma, n=47; RCC, n=27). ORR in melanoma and RCC cohorts was 9% (95% CI, 2% to 21%; n=4) and 14% (95% CI, 3% to 35%; n=3), respectively; disease control rate was 50% (95% CI, 35% to 65%; n=23) and 50% (95% CI, 28% to 72%, n=11), respectively, with stable disease ≥6 months observed in 3 (7%) and 2 (9%) patients, respectively. The most common nemvaleukin-related treatment-emergent adverse event of grade 3–4 was neutropenia (melanoma, n=27 (57%); RCC, n=9 (33%)). No patients in either cohort experienced grade ≥3 treatment-emergent adverse events (TEAEs) of cytokine release syndrome or infusion-related reaction. There were no reported capillary leak syndrome TEAEs. Pharmacokinetic parameters for extent and duration of nemvaleukin exposure were similar between the two cohorts. Increases in peripheral CD8+ T-cell and natural killer cell populations from baseline were similar between the two cohorts, with minimal changes in regulatory T cells observed.Conclusions Nemvaleukin demonstrated pharmacodynamic proof of mechanism, with single-agent antitumor activity and manageable safety in patients with advanced melanoma and RCC.Trial registration number NCT02799095.https://jitc.bmj.com/content/13/8/e010777.full |
| spellingShingle | Xiaomin He Emiliano Calvo David F McDermott Valentina Boni Olivier Dumas Arvind Chaudhry Sang Joon Shin Seth D Rosen Philip R Debruyne Ulka N Vaishampayan Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial Journal for ImmunoTherapy of Cancer |
| title | Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial |
| title_full | Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial |
| title_fullStr | Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial |
| title_full_unstemmed | Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial |
| title_short | Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial |
| title_sort | nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma results from the phase 1 2 non randomized artistry 1 trial |
| url | https://jitc.bmj.com/content/13/8/e010777.full |
| work_keys_str_mv | AT xiaominhe nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT emilianocalvo nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT davidfmcdermott nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT valentinaboni nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT olivierdumas nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT arvindchaudhry nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT sangjoonshin nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT sethdrosen nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT philiprdebruyne nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial AT ulkanvaishampayan nemvaleukinalfamonotherapyinpatientswithadvancedmelanomaandrenalcellcarcinomaresultsfromthephase12nonrandomizedartistry1trial |